Novo Nordisk A/S experienced a significant decline in its stock value, as shares dropped nearly 10% in premarket trading following the announcement that oral semaglutide did not effectively slow disease progression in two large Phase 3 trials focused on Alzheimer’s disease.
The trials, known as evoke and evoke+, were randomized and double-blind studies designed to evaluate the effectiveness of oral semaglutide against a placebo in patients exhibiting early symptoms of Alzheimer’s. Over a comprehensive duration of 104 weeks, with an additional 52-week extension, these studies enrolled a total of 3,808 participants.
Despite the completion of the trials, Novo Nordisk reported that both studies failed to achieve their primary endpoint, which was measured using the Clinical Dementia RatingSum of Boxes (CDR-SB). This outcome led the company to announce the discontinuation of plans for a one-year secondary extension initially intended for the trials. However, the company indicated that treatment did bring about some favorable changes in certain Alzheimer’s biomarkers, suggesting a nuanced perspective on the drug’s impact.
Management reassured stakeholders that the safety profile of oral semaglutide remained consistent with previous studies involving the medication. The trial results have been viewed as a setback for the potential repurposing of the diabetes and obesity drug to address cognitive decline symptoms associated with Alzheimer’s disease.
In light of these developments, analysts have expressed concerns that the disappointing results may dampen investor enthusiasm around diversifying clinical pipelines in Alzheimer’s treatment and could create added pressure for other pharmaceutical companies exploring similar avenues in their research efforts.
